MedTrace Logo

Study of JTM104 Injection vs. Juvederm in Treating Moderate to Severe Nasolabial Folds

NCT07265791 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-12-05

No results posted yet for this study

Summary

Study of JTM104 Injection vs. Juvederm in Treating Moderate to Severe Nasolabial Folds

Conditions

  • Nasolabial Folds, Wrinkles

Interventions

BIOLOGICAL

JTM104

JTM104 contains 22.8 mg/mL cross-linked hyaluronic acid, 1.2 mg/mL hyaluronic acid, and 3 mg/mL lidocaine. The product will be injected into the nasolabial folds, with a maximum volume of 1 mL per side.

BIOLOGICAL

Juvederm® ULTRA PLUS XC

Juvederm® ULTRA PLUS XC contains 22.8 mg/mL cross-linked hyaluronic acid, 1.2 mg/mL hyaluronic acid, and 3 mg/mL lidocaine. The product will be injected into the nasolabial folds, with a maximum volume of 1 mL per side.

Sponsors & Collaborators

  • Jetema Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-03
Primary Completion
2026-06-30
Completion
2027-01-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07265791 on ClinicalTrials.gov